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Does furosemide decrease
morbidity or mortality 
for patients with diastolic
or systolic dysfunction?
■ Evidence-Based Answer 
No large-scale randomized, placebo-controlled tri-
als evaluate furosemide’s effect on mortality and
long-term morbidity in diastolic or systolic dys-
function. In short-term studies, furosemide reduces
edema, reduces hospitalizations, and improves
exercise capacity in the setting of systolic dysfunc-
tion (strength of recommendation [SOR]: B, based
upon low-quality randomized controlled trials).
Furosemide and other diuretics reduce sympto-
matic volume overload in diastolic and systolic
dysfunction (SOR: C, based on expert opinion). 
There is potential morbidity with the use of
high-dose loop diuretics (volume contraction,
electrolyte disturbances, and neuroendocrine acti-
vation).1–3 Use of high-dose loop diuretics for sys-
tolic dysfunction is associated with increased mor-
tality, sudden death, and pump failure death
(SOR: B, based on retrospective analyses of large-
scale randomized controlled trials). However,
diuretic resistance or disease severity may explain
these latter findings.
■ Evidence Summary
Faris et al4 conducted a meta-analysis of random-
ized controlled trials that used diuretics (per-
tanide, furosemide, furosemide-hydrochloroth-
iazide) in congestive heart failure (TABLE).4 Of the
18 trials, 8 were placebo-controlled and 10 used
active controls (diuretics vs angiotensin-convert-
ing enzyme [ACE] inhibitors, digoxin, or
ibopamine, a dopamine agonist). Three placebo-
controlled trials (N=221) showed an absolute risk
reduction in death of 8% in diuretic-treated
patients (number needed to treat [NNT]=12.5).
Four placebo-controlled trials (N=448) showed a
significantly lower rate of admissions for worsen-
ing failure among diuretic-treated patients
(NNT=8.5), and 4 of the active-controlled trials
(N=150) showed a nonsignificant trend toward
decreased admissions. Six active-controlled stud-
ies (N=174) showed significantly increased exer-
cise capacity for patients on diuretics. One of these
latter trials also assessed quality of life, edema,
and New York Heart Association (NYHA) class,
and demonstrated no change in these outcomes in
the treatment and placebo groups.5
The studies used in this meta-analysis had
numerous shortcomings: the individual trials 
had small numbers of patients (N=14–139), short
follow-up periods (typically 4–8 weeks), and inad-
equate statistical power to clearly demonstrate
morbidity/mortality reductions. There was signifi-
cant heterogeneity between studies. Crossover
studies were included, some studies did not clear-
ly report masking and assessment of outcome
measures, and assessment of study validity was
not clear. Studies employed a variety of diuretic
types and doses, used different controls, and did
not clarify whether patients’ congestive heart 
failure was caused primarily by diastolic or sys-
tolic dysfunction.
It is worth noting that diuretic use also carries
some risk. One large retrospective study evaluated
6796 patients using potassium-sparing diuretics vs
non–potassium-sparing diuretics in the Studies of
Left Ventricular Dysfunction (SOLVD) trial.6 Rates
of hospitalization or death from worsening conges-
tive heart failure were significantly higher in the
non–potassium-sparing diuretic population than in
the nondiuretic population (relative risk [RR]=1.31,
95% confidence interval [CI], 1.09–1.57; number
needed to harm=5.78). This increased risk was not
found for patients taking potassium-sparing diuret-
ics (RR=0.99; 95% CI, 0.76–1.30).
Another retrospective study of SOLVD
patients found a significant and independent asso-
ciation with increased risk of arrhythmic death
among patients taking non–potassium-sparing
diuretics (RR=1.33; 95% CI, 1.05–1.69).7
A retrospective study of 1153 patients with
NYHA Class III to IV heart failure, who were
enrolled in the Prospective Randomized
Amlodipine Survival Evaluation (PRAISE), found
high diuretic doses to be independently associated
with mortality (adjusted hazard ratio [HR]=1.37;
P=.004), sudden death (HR=1.39; P=.042), and
pump failure death (HR=1.51; P=.034).8
The authors caution that there is no proof of
causation between furosemide and death; diuret-
ic resistance may explain the poor outcomes, or
the use of loop diuretics at high doses may be
proxy of more severe illness, and thus poorer
outcome.
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T A B L E
TRIAL RESULTS 
OUTCOME DESCRIPTION N (REPORTED AS OR) 95% CI P VALUE NNT
Death 3 placebo-controlled 221 0.25 0.07–0.84 .03 12.5
Admissions 4 placebo-controlled 448 0.31 0.15–0.62 .001 8.5
4 active-controlled 150 0.34 0.10–1.21 .10 12.8
Exercise 6 active-controlled 174 0.37 0.10–0.64 .007 *
capacity
*Unable to calculate NNT due to lack of uniform reporting of exercise times.
OR, odds ratio; CI, confidence interval; NNT, number needed to treat.
Source: Faris et al, Int J Cardiol 2002.4
Clinical effects of diuretics in congestive heart failure
■ Recommendations from Others
The American College of Cardiology recommends
using diuretics in the setting of left ventricular sys-
tolic dysfunction and fluid retention (level of evi-
dence [LOE]: A), and recommends using diuretics
in diastolic dysfunction to control pulmonary 
congestion and peripheral edema (LOE: C).9
The European Society of Cardiology notes
that no randomized controlled trials have assessed
survival effects of diuretics in congestive heart fail-
ure, but recommends using diuretics for sympto-
matic treatment of volume overload (LOE: A).
This society also cites evidence that diuretic use
improves exercise tolerance (LOE: B). They rec-
ommend that diuretics be used always in addition
to an ACE inhibitor, that loop diuretics be used if
symptoms are more than mild and if glomerular
filtration rate (GFR) <30 cc/min, and that thiazide
diuretics can be used with loop diuretics for syner-
gistic effects in severe congestive heart failure.10
Amrit Singh, MD, Jean Blackwell, MLS, 
University of North Carolina, Chapel Hill
■ Clinical Commentary
Helpful in the acute setting, diuretics
shouldn’t be used alone chronically
Furosemide and the other loop diuretics are
very satisfying to use clinically. The patient in
heart failure arrives at the hospital dypsneic,
cyanotic, and terrified. After a single large dose
of medication, the patient diureses and begins
to feel good again quite quickly.  
The practitioner, however, needs to be 
wary of the resulting impression that diuretics
are “good” for heart failure. ACE inhibitors, 
beta blockers, and (in severe cases) spironolac-
tone are “good” for heart failure because they
prolong lives. One must not allow diuretic 
therapy—started for acute decompensation—
to prevent use of more important long-term
medications by causing dehydration, hypoten-
sion, or electrolyte disturbances. 
Jon Neher, MD, 
Valley Medical Center, Renton, Wash
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What is the best treatment
for gastroesophageal reflux
and vomiting in infants?
■ Evidence-Based Answer 
The literature on pediatric reflux can be divided
into studies addressing clinically apparent reflux
(vomiting or regurgitation) and reflux as measured
by pH probe or other methods (TABLES 1 AND 2).
Sodium alginate reduces vomiting and improves
parents’ assessment of symptoms (strength of 
recommendation [SOR]: B, small randomized 
controlled trial [RCT]). Formula thickened with
rice cereal decreases the number of postprandial
emesis episodes in infants with gastroesophageal
reflux disease (GERD) (SOR: B, small RCT). 
There are conflicting data on the effect of
carob bean gum as a formula thickener and its
effect on regurgitation frequency (SOR: B, small
RCTs). Metoclopramide does not affect vomiting
or regurgitation, but is associated with greater
weight gain in infants over 3 months with reflux
(SOR: B, low-quality RCTs). 
Carob bean gum used as a formula thickener
decreases reflux as measured by intraluminal
impedance but not as measured by pH probe
(SOR: B, RCT). Omeprazole and metoclopramide
each improve the reflux index as measured by
esophageal pH probe (SOR: B, RCT). 
Evidence is conflicting for other commonly
used conservative measures (such as positional
changes) or other medications for symptomatic
relief of infant GERD. There is very limited evi-
dence or expert opinion regarding breastfed
infants, particularly with regard to preservation of
breastfeeding during therapy.
■ Evidence Summary
Regurgitation (“spitting up”) and gastroe-
sophageal reflux are common in infants. In a cross-
sectional survey of 948 parents of healthy infants
aged 0 to 13 months, regurgitation occurred daily
in half of infants from birth to 3 months old,
peaked to 67% at age 4 months, and was absent in
95% by age 12 months.1 Gastroesophageal disease
(GERD) is characterized by refractory symptoms
or complications (pain, irritability, vomiting, fail-
ure to thrive, dysphagia, respiratory symptoms, or
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■ Is DEET safe for children?
■ What causes cheilitis and how 
do you treat it?
■ Should a Cytobrush be used for
Pap smears in pregnant patients?
■ What is the best approach to the
evaluation of hirsutism?
■ Does reduction in physical activity
in adolescents with mononucleosis
reduce splenic rupture?
■ What are the diagnostic criterial 
for HELLP syndrome in pregnant
women?
■ What is the appropriate diagnostic
evaluation of fibroids?
Look for these 
Clinical Inquiries
Coming soon in JFP
